Patents by Inventor Elias Lazarides

Elias Lazarides has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
    Publication number: 20140341892
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
  • Anti-alpha2 integrin antibodies and their uses
    Patent number: 8759009
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: June 24, 2014
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • Humanized antibodies specific for von Willebrand factor
    Patent number: 8236315
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 7, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
  • ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
    Publication number: 20110135635
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: August 17, 2010
    Publication date: June 9, 2011
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • Anti-?2 integrin antibodies and their uses
    Patent number: 7807794
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: October 5, 2010
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
  • HUMANIZED ANTIBODIES SPECIFIC FOR VON WILLEBRAND FACTOR
    Publication number: 20090232804
    Abstract: The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
    Type: Application
    Filed: January 23, 2009
    Publication date: September 17, 2009
    Applicant: GLENMARK PHARMACEUTICALS, S.A.,
    Inventors: Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
  • Anti-alpha2 integrin antibodies and their uses
    Publication number: 20070128190
    Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.
    Type: Application
    Filed: November 17, 2006
    Publication date: June 7, 2007
    Inventors: Elias Lazarides, Catherine Woods, Mark Bernard
  • Method to identify targeting molecules
    Publication number: 20040110681
    Abstract: Methods for validating the in vivo targeting specificity of compounds according to pharmacokinetic criteria are described. An improved method to generate a library of peptides with reduced complexity and enhanced candidate compound membership comprises expressing oligonucleotides encoding cyclic peptides with randomized coding sequences representing the non-bridging amino acids. Also described is determination of structure activity relationships using kinetic technique using in vivo panning. Design of targeting compounds with appropriate space/charge/hydrophobicity conformations can be based on the results of these kinetic structure activity relationship (kSAR) determinations. In addition, compositions resulting from this methodology are useful in treating neuroinflammatory and lung disorders, and disorders involving disseminated blood cell coagulopathy interactions with vascular endothelium.
    Type: Application
    Filed: August 8, 2003
    Publication date: June 10, 2004
    Inventors: Xiao-Min Fan, Elias Lazarides, Catherine M. Woods